Fresenius Kabi USA, LLC, a prominent subsidiary of Fresenius Kabi AG, is headquartered in the United States and operates extensively across North America. Founded in 1996, the company has established itself as a leader in the healthcare industry, specialising in lifesaving medicines and technologies. Fresenius Kabi focuses on critical care, infusion therapy, and biosimilars, offering a diverse range of products that are distinguished by their quality and reliability. With a commitment to enhancing patient care, Fresenius Kabi has achieved significant milestones, including the development of innovative drug delivery systems and a robust portfolio of intravenous solutions. The company is recognised for its strong market position, consistently ranking among the top providers in its field, and is dedicated to advancing healthcare through sustainable practices and cutting-edge research.
How does Fresenius Kabi USA, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fresenius Kabi USA, LLC's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fresenius Kabi USA, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Fresenius SE & Co. KGaA, which cascades emissions data and climate commitments from its parent organisation. As of now, there are no documented reduction targets or climate pledges specific to Fresenius Kabi USA, LLC. The absence of specific initiatives or targets indicates a potential area for development in their sustainability strategy. The emissions data and performance metrics are inherited from Fresenius SE & Co. KGaA, which operates under broader industry standards for climate action. This relationship suggests that any climate commitments or emissions reductions would align with the overarching goals set by the parent company. In summary, while Fresenius Kabi USA, LLC does not currently report specific emissions figures or reduction targets, it is part of a larger corporate structure that may influence its future climate commitments and sustainability initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Fresenius Kabi USA, LLC's Scope 3 emissions, which increased by 1% last year and increased by approximately 1% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 44% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fresenius Kabi USA, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.